Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8486574 | 0.96 | POLB (0.48) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL6563271 | 0.89 | POLB (0.46) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL2037515 | 0.88 | SMN1; SMN2 (0.46) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL6300484 | 0.88 | POLB (0.43) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL20025128 | 0.86 | POLB (0.47) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL6566582 | 0.85 | POLB (0.47) | POLBLMNATSHROPRM1GAA | |
| SCHEMBL6302650 | 0.84 | POLB (0.43) | POLBHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL17282348 | 0.83 | TSHR (0.39) | FFAR4LMNATSHROPRM1SMN1; SMN2 | |
| SCHEMBL19317381 | 0.83 | POLB (0.49) | POLBLMNATSHRGAASMN1; SMN2 | |
| SCHEMBL7500028 | 0.83 | POLB (0.52) | POLBLMNATSHRGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015179823-A2 | LUNG LOCALIZED INHIBITORS OF ALPHA(V)BETA 6 | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-11-26 | — | — | WO | disclosed |
| EP-2512523-A1 | LABELLED INTEGRIN BINDERS | GE Healthcare UK Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| CN-102652023-A | Labelled integrin binders | GE HEALTHCARE LTD | 2012-08-29 | — | — | CN | disclosed |
| WO-2011073340-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | POLB 4645/4885HDAC1 917/4885HDAC2 974/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | POLB 4640/4885HDAC1 1127/4885HDAC2 962/4885 |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | ITGAV, ITGB6, ITGA2B | POLB 4333/4885HDAC1 962/4885HDAC2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.